Browse by Poster Presenter

Skip to main content

ASCPT 2024 Annual Meeting Main banner

Browse by Poster Presenter

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

N
Nahid, Noor

Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, University of Florida College of Pharmacy
PII-080 - IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
Noor Nahid
Favorite
PT-017 - IMPACT OF CYP2D6 INHIBITORS ON PAIN CONTROL BY THE OPIOIDS
Noor Nahid
Favorite
Na, Joo Young

The Ohio State University
PII-127 - MODELING AND SIMULATION TO EXPLORE MECHANISMS OF PHARMACOKINETIC DRUG-DRUG INTERACTIONS OF ABEMACICLIB AND OLAPARIB IN PATIENTS WITH RECURRENT PLATINUM-RESISTANT OVARIAN CANCER
Joo Young Na
Favorite
Neal, Reem

UT Southwestern Medical Center
LB-006 - ARTERIAL STIFFNESS AND SYSTEMIC VASCULAR CORRELATES OF BRAIN AMYLOIDOSIS AND PRECLINICAL AD
Reem Neal
Favorite
Nepal, Mahesh

The Ohio State University
PII-041 - A CHEMICAL BIOLOGY STRATEGY FOR PREDICTING OATP1B-TYPE TRANSPORTER-MEDIATED DRUG-DRUG INTERACTION (DDI) LIABILITIES
Mahesh Nepal
Favorite
Nguyen, Duyen

Division of Therapeutic Performance II, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
PII-187 - ASSESSMENT OF MALE INFERTILITY RISKS TO SUPPORT PRODUCT-SPECIFIC GUIDANCE DEVELOPMENT FOR GENERIC ORAL PRODUCTS.
Duyen Nguyen
Favorite
Nguyen, Van

BioPharma Services Inc.
E-003 - UNLOCKING THE DATA MYSTERY: A SIMULATION BASED DECISION GUIDE TO EVALUATE MISSING DATA IN BIOAVAILABILITY AND BIOEQUIVALENCE STUDIES.
Van Nguyen
Favorite
Niimura, Takahiro

Tokushima University
PII-189 - EVALUATION OF CARDIOVASCULAR TOXICITY PROFILE OF ALK INHIBITORS USING ADVERSE EVENT REPORTING DATABASE
Takahiro Niimura
Favorite
Niloy, Kumar Kulldeep

St. Jude Children's Research Hospital, The University of Tennessee Health Science Center
LB-027 - PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO PREDICT HUMAN DOSE OF MITHRAMYCIN ANALOGUE FOR THE TREATMENT OF EWING SARCOMA
Kumar Kulldeep Niloy
Favorite
LB-028 - PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO SUPPORT PEDIATRIC DOSING OF OLVEREMBATINIB IN CHILDREN WITH RELAPSED OR REFRACTORY PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Kumar Kulldeep Niloy
Favorite
Nishii, Rina

Bristol Myers Squibb
PII-016 - CELLULAR KINETICS OF ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, LISOCABTAGENE MARALEUCEL (LISO-CEL) AND ITS ASSOCIATION WITH EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
Rina Nishii
Favorite
Noorani, behnam

AbbVie, Inc., Chicago, Illinois, USA
PII-061 - PHARMACOKINETICS (PK) OF MIRZOTAMAB CLEZUTOCLAX (MIRZO-C) IN PATIENTS WITH RELAPSED AND REFRACTORY SOLID TUMORS: FIRST IN HUMAN STUDY RESULTS
behnam Noorani
Favorite
Norris, Madeline

University of Florida
PII-085 - POTENTIAL HEALTHCARE DISPARITIES AMONG PATIENTS WHO REGISTER FOR NOVEL PHARMACOGENETICS CONSULTATION SERVICE
Madeline Norris
Favorite